215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin

• Robyn Puro,
• Prabir Chakraborty,
• John Richards,
• Ronald Hiebsch,
• Michael Donio,
• W Casey Wilson,
• Benjamin Capoccia,
• Carrie Brachmann,
• Vicki Sung,
• Arun Kashyap,
• Daniel Pereira

Affiliations

Robyn Puro

Arch Oncology, St. Louis, MO, USA

Prabir Chakraborty

Arch Oncology, St. Louis, MO, USA

John Richards

Arch Oncology, St. Louis, MO, USA

Ronald Hiebsch

Arch Oncology, St. Louis, MO, USA

Michael Donio

Arch Oncology, St. Louis, MO, USA

W Casey Wilson

Arch Oncology, St. Louis, MO, USA

Benjamin Capoccia

Arch Oncology, St. Louis, MO, USA

Carrie Brachmann

Arch Oncology, St. Louis, MO, USA

Vicki Sung

Arch Oncology, St. Louis, MO, USA

Arun Kashyap

Arch Oncology, St. Louis, MO, USA

Daniel Pereira

Arch Oncology, St. Louis, MO, USA